NCT01988961View on ClinicalTrials.gov

A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

PHASE2CompletedINTERVENTIONAL

Enrollment

103

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

February 28, 2015

Study Completion Date

January 31, 2016

Conditions

Colitis, Ulcerative

Interventions

BIOLOGICAL

Golimumab

SC injections

Trial Locations (45)

Unknown

La Jolla

National City

Denver

Golden

Maitland

Winter Park

Zephyrhills

Suwanee

Idaho Falls

Crestview Hills

Rochester

Kansas City

Cincinnati

Columbia

Chesapeake

Ghent

Leuven

Roeselare

Rousse

Sofia

Victoria

London

Vaughan

Hradec Králové

Prague

Grenoble

Lille

Paris

Hanover

Kiel

Budapest

Gyula

Mosonmagyaróvár

Amsterdam

Sittard-Geleen

Elblag

Lodz

Staszów

Wroclaw

Moscow

Nizhny Novgorod

Saint Petersburg

Kharkiv

Kyiv

Vinnitsya

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT01988961 - A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis | Biotech Hunter | Biotech Hunter